AstraZeneca has agreed to pay $103 million to settle class-action claims arising out of the company inflating the wholesale price of cancer and asthma treatments. The first settlement includes $13 million for consumers and health insurers in Massachusetts, and $90 million for claimants outside of the state. The class-action lawsuit alleged that AstraZeneca inflated the average wholesale price of Zoladex, a cancer drug, and Pulmicort Respules, a treatment used to prevent asthma symptoms in children. This is one of the fraud cases that have been labeled AWP cases and the facts should be familiar to the Alabama Supreme Court. Apparently, judges in other states take a different view on the law applicable to these cases. At least AstraZeneca must believe that they do since the company is settling cases.
Source: The News Journal
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.